Papilledema News and Research

RSS

Papilledema is a term which literally means “swelling of the optic disc”, but whose meaning has narrowed since 1908, when it was coined.

Understanding the role of cerebral venous flow in idiopathic intracranial hypertension

Idiopathic intracranial hypertension (IIH) is a rare and poorly understood neurological disorder that affects 1 to 20 people per 100,000-most often women of childbearing age.

22 Jul 2026

New study sheds light on vision loss in idiopathic intracranial hypertension

If untreated, a disorder of high brain pressure called idiopathic intracranial hypertension can lead to vision loss. But this disorder can develop without noticeable symptoms, making it hard to catch.

30 Oct 2025

Diabetes drugs linked to higher risk of rare optic nerve damage

...

14 Aug 2025

Diabetes medication shows promise in cutting migraine days by more than half

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented today at the European Academy of Neurology (EAN) Congress 2025.

20 Jun 2025

Ferring announces FDA approval of ZOMACTON for injection in four new pediatric indications

Ferring Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved ZOMACTON for injection in four additional pediatric indications

20 Jul 2018

Failure to accurately assess optic nerve drives IIH overdiagnosis

Researchers put overdiagnosis of idiopathic intracranial hypertension (IIH) down to inaccurate ophthalmoscopic examination in headache patients and wrongly suspecting the condition in young obese women with headaches.

7 Jan 2016

Sleep disorders linked to eye disease

If a good night's sleep helps the brain and body perform better, it's a good guess that sleep problems can cause more than just fatigue.

11 Nov 2008

Sleep disorder linked to eye disease

Research has already suggested that sleep problems can cause more than just tiredness - they have been linked to cardiovascular disease, cerebrovascular disease and metabolic disorders, and are also thought to raise the risk of obesity and diabetes.

10 Nov 2008

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

27 Aug 2008

FDA approves Norditropin for short stature in children with Noonan syndrome

Novo Nordisk has announced that Norditropin (somatropin[rDNA origin] injection) received U.S. Food and Drug Administration (FDA) approval for the treatment of short stature in children with Noonan syndrome.

3 Jun 2007

Gleevec available to patients in post-surgical GIST study

Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.

15 Apr 2007